Incannex Healthcare Announces First Patient Dosed In Phase 2 DReAMzz Dose-Optimization Study Of IHL-42X In Obstructive Sleep Apnea Across 14 U.S. Sites

Loading news article.

Incannex Healthcare Announces First Patient Dosed In Phase 2 DReAMzz Dose-Optimization Study Of IHL-42X In Obstructive Sleep Apnea Across 14 U.S. Sites | WAPE

Incannex Healthcare Announces First Patient Dosed In Phase 2 DReAMzz Dose-Optimization Study Of IHL-42X In Obstructive Sleep Apnea Across 14 U.S. Sites

Article summary

Related companies

Comments —